Form 4: Agios Director Converts RSUs to Common Stock

Agios Pharmaceuticals Director Cynthia Smith converted 2,302 restricted stock units into common stock on August 11, 2025, increasing her direct beneficial ownership to 12,414 shares.

Summary

• Cynthia Smith, a Director at Agios Pharmaceuticals, Inc. (AGIO), reported a change in her beneficial ownership.
• On August 11, 2025, Smith acquired 2,302 shares of common stock through the exercise of restricted stock units (RSUs).
• The transaction code 'M' indicates an exercise or conversion of a derivative security.
• The price for the acquired common stock was $0, consistent with RSU vesting.
• Following this transaction, Smith directly beneficially owns 12,414 shares of common stock.
• Concurrently, 2,302 restricted stock units were disposed of as they were converted into common stock, leaving 0 RSUs beneficially owned.
• The RSUs were originally granted on August 11, 2022, and began vesting in three equal annual installments starting August 11, 2023.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (RSU vesting) which is generally neutral but slightly positive as it increases direct insider ownership, aligning interests with shareholders. No negative or significant positive news is present.

Positives

• Conversion of restricted stock units into common stock by a director indicates continued alignment of interests with shareholders.
• The increase in direct common stock ownership to 12,414 shares by a director demonstrates ongoing commitment to the company.

Future Outlook

NA

Industry Context

This transaction is a routine insider filing, common in the biotechnology and pharmaceutical industries where executive and director compensation often includes equity awards like restricted stock units. Such vesting events are standard practice for aligning management incentives with shareholder value.

Comparison to Industry Standards

• The vesting and conversion of restricted stock units at a $0 exercise price is a standard compensation practice across publicly traded companies, particularly in the biotech sector.
• This aligns with typical equity compensation structures seen at comparable companies like Vertex Pharmaceuticals (VRTX) or Sarepta Therapeutics (SRPT), where executives receive RSUs that vest over time, converting into common stock upon vesting.
• The transaction itself does not provide specific performance metrics for direct comparison to industry benchmarks, but the mechanism of equity compensation is consistent with industry norms.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns her interests with those of shareholders.

Key Dates

Recommendation

This Form 4 filing details a routine vesting and conversion of restricted stock units by a director. While it increases insider ownership, which is generally a positive signal of alignment, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It is a standard compensation event.

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Transaction, Cynthia Smith, Restricted Stock Units, RSU Vesting, Common Stock, Director Ownership, Biotechnology, Pharmaceuticals